Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1Phase 2 1

Status

Completed 126Terminated 49Unknown 22Recruiting 15Withdrawn 11Active not recruiting 4Suspended 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 2Sarcoma 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 2Thrombocythemia, Essential 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pinealoma 1Pancreatic Cancer Metastatic 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Myeloproliferative Disorders 1Medulloblastoma 1Leukemia, Myelomonocytic, Chronic 1Histiocytosis, Langerhans-Cell 1Ependymoma 1Carcinoma 1Brain Neoplasms 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Celecoxib × Clear all
NCT02574728 2026-03-02

AflacST1502

Emory University

Phase 2 Active not recruiting
46 enrolled
CNSMyeloidSarcoma

Brain Neoplasms, Carcinoma, Ependymoma, Histiocytosis, Langerhans-Cell, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT06076837 2026-01-12

The Seven Trial: Exploiting the Unfolded Protein Response

HonorHealth Research Institute

Phase 1 Active not recruiting
6 enrolled
Gastrointestinal

Pancreatic Cancer Metastatic

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

AbbVie

Phase 1 Active not recruiting
85 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT00268476 2023-04-18

STAMPEDE

Medical Research Council

Phase 2/3 Active not recruiting
11,992 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡